Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]
Lina Silva Salinas2022-09-19T11:05:53+02:00U. Hasler-Strub, A. Mueller, Q. Li, B. Thuerlimann, K. Ribi, S. Gerber, R. von Moos, M. Fehr, C. Rochlitz, K. Zaman, S. Aebi, A. Hochstrasser, U. Gick, D. Baertschi, S. Greuter, A. Schreiber, C. Caspar, A. Trojan, R. Condorelli, T. Ruhstaller, for the Swiss Group for Clinical Cancer Research (SAKK). Published: September 18, 2022 DOI: https://doi.org/10.1016/j.jgo.2022.09.001